ChinaBio Today -- Two Japanese drug companies, Teijin Pharma and Astellas, have teamed up to develop and market Teijin’s treatment for gout, TMX-67 (febuxostat), in China and Hong Kong. TMX-67 is an oral, once-daily, non-purine selective inhibitor of xanthine oxidase that is, according to Teijin, especially notable for being well-tolerated by patients with mild renal impairment. More details...
